Degenerative disc disease (DDD) involves the breakdown of intervertebral discs — the cushioning structures between vertebrae. As discs degenerate, inflammatory cytokines (TNF-α, IL-1β, IL-6) accumulate, contributing to pain, nerve irritation, and progressive structural breakdown. MSC therapy targets both the inflammatory environment and the disc tissue itself.
Mechanisms
Reducing Disc Inflammation
MSCs modulate the inflammatory response within and around the disc by secreting anti-inflammatory cytokines and reducing pro-inflammatory signaling. Research published in spine and regenerative medicine literature demonstrates that MSC therapy may reduce inflammatory markers and improve pain scores in patients with DDD.
Supporting Disc Cell Survival
Healthy discs rely on specialized cells in the nucleus pulposus and annulus fibrosus to maintain disc structure, hydration, and flexibility. During degeneration, these cells decrease in number and function. MSCs support disc cell health through paracrine signaling — releasing growth factors and cytokines that promote cellular survival, tissue repair, and extracellular matrix maintenance.
Inhibiting Further Degradation
Catabolic enzymes (MMPs) degrade disc matrix in DDD. MSCs have been shown to inhibit MMP expression in disc tissue, slowing the rate of further structural breakdown. TGF-β secreted by MSCs also stimulates disc matrix repair.
Delivery and Expectations
For DDD, MSCs are typically delivered via targeted intradiscal injection (directly into the affected disc) combined with IV infusion for systemic anti-inflammatory benefit. Pain reduction and functional improvement are typically seen at 3–6 months post-treatment. Structural disc regeneration (increased disc height on MRI) has been reported in some patients but is not a primary outcome target.